NovaMed Pharmaceuticals, Inc.
http://www.novamed.com.cn/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From NovaMed Pharmaceuticals, Inc.
Chinese Investor Consortium Buys SciClone But Relisting Possible
Against a background of positive changes to regulations and policies on pharmaceutical marketing in China, US-based SciClone has accepted a buyout offer from a consortium of Chinese investors, but may relist in China in the future.
Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China
Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.
Death By EDL Inclusion? Pfizer And SciClone Drop Cancer Drugs In China
Manufacturers are reevaluating products and reducing sales forces in response to pricing pressure that includes an expanded Essential Drug List in China.
With An Eye On China’s Growing PAD Market, SciClone Teams Up With Taiwan Liposome Co.
Looking to take on Bayer/UCB’s Prostavasin and a local blockbuster from Beijing Tide Pharmaceutical Co., SciClone will jump into China’s peripheral arterial disease market with what it hopes is a differentiated product developed by TLC.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice